

RNAi – The RIGHT Track to Therapy

Symposium 3-5 November 2008

The International Auditorium, Brussels, Belgium

Programme

Monday, 3 November

Time	Speaker	Titel
12.00 – 14.00	Registration	
14.00 – 14.30	Welcome	
14.30 – 15.00	Introductory lecture:	
	Arndt Borkhardt Heinrich Heine University, Duesseldorf, Germany	Conventional therapy versus innovative approaches like RNAi
15.00 – 18.15 incl. coffee break 30 min	Session I: Chemical modifications of siRNAs and delivery strategies (Modifications, formulations, targeted delivery, pharmacokinetics)	
	Jesper Wengel University of Southern Denmark, Odense, Denmark	Optimization of siRNAs - Modifications, formulations, delivery and pharmacokinetics
	Jesper Bramsen University of Aarhus, Denmark	Chemical engineering of siRNAs for in vivo delivery
	Muthia Manoharan Alnylam Pharmaceuticals, Cambridge, USA	Delivering RNAi therapeutics using Chemistry
	Gert Storm University of Utrecht, The Netherlands	New formulations for targeted siRNA delivery
	Motomu Shimaoka Harvard Medical School, Boston, USA	Integrin-targeted siRNA delivery for leukocyte-directed RNAi therapeutics
	Andreas Voigt Capsulation NanoScience AG, Berlin, Germany	Title to be announced
18.15 – 19.15	Keynote lecture:	
	John Mattick University of Queensland, Brisbane, Australia	The human genome as an RNA machine
19.15 – 21.00	Reception	

Tuesday, 4 November

Time	Speaker	Titel
9.00 – 12.30 incl. coffee break 30 min	Session II: Vector systems for RNA interference approaches (Viral delivery systems, miRNA regulated vector systems, non-viral vectors)	
	Beverly L. Davidson University of Iowa, Iowa City, USA	RNAi for dominant neurodegenerative diseases: approaches to therapy and dissecting disease pathogenesis
	Patrick Aebischer Ecole Polytechnique Fédérale de Lausanne, Switzerland	RNAi for neurodegenerative diseases: the scale-up challenge
	Ben Berkhout University of Amsterdam, The Netherlands	RNAi gene therapy against the moving target HIV-1
	Kevin V. Morris The Scripps Research Institute, La Jolla, USA	Mobilization competent lentiviral vector mediated sustained transcriptional modulation of HIV-1 expression
	Barbara Demeneix CNRS, Paris, France	Optimising non-viral delivery of RNAi to neurogenic areas of the mouse brain
	Nicole Déglon Institute of biomedical imaging, Orsay Cedex, France	Long-term and global silencing of huntingtin as therapeutic strategy for Huntington's disease
12.30 – 14.00	Lunch	
14.00 – 15.30	Poster session	
15.30 – 18.30 incl. coffee break 20 min	Session III: RNA interference towards therapeutic approaches (In vivo models, clinical trials)	
	Patrick Arbuthnot University of the Witwatersrand, Johannesburg, South Africa	Optimising RNAi effecters to counter chronic hepatitis B virus infection
	Maria Mota University of Lisbon, Portugal	Approach malaria from the host side: from functional genomics to "systems biology"
	Reinhold Schäfer Charité, Berlin, Germany	Perturbation of oncogenic signaling and transcriptional control – an integrated study combining RNA interference and expression profiling
	Judy Lieberman Harvard Medical School, Boston, USA	Targeting Cancer Stem Cells
	Takahiro Ochiya National Cancer Research Center, Tokyo	MicroRNA as a novel tool for cancer therapy

	Giorgio Inghirami University of Torino, Italy	Title to be announced
18.30 – 19.00	Plenary lecture:	
	Gunther Hartmann University of Bonn, Germany	Therapeutic application of RNA oligonucleotides combining RNAi and immunostimulation
19.30	Speakers dinner	

Wednesday, 5 November

Time	Speaker	Titel
9.00 – 12.30 incl. coffee break 30 min	Session IV: RNA interference towards therapeutic approaches (In vivo models, clinical trials)	
	George Kollias Biomedical Sciences Research Center "Al. Fleming", Vari, Greece	Validation of therapeutic siRNA approaches in animal models of TNF/TNFR mediated chronic inflammatory diseases
	Alexander Karlas Max Planck Institute for Infection Biology, Berlin, Germany	Global identification and therapeutic knock down of host cell factors essential for influenza replication
	Cristina M. Rondinone Hoffmann-La Roche Inc, Nutley, USA	Title to be announced
	Jörg Kaufmann Silence therapeutics, Berlin, Germany	Development of liposomal siRNA (AtuPlex) for RNAi mediated therapeutic applications
	Yoshiro Niitsu Sapporo Medical University, Japan	Treatment of liver cirrhosis with siRNA Hsp47 encapsulated in VA coupled liposome
12.30 – 13.00	Thomas F. Meyer Max Planck Institute for Infection Biology, Berlin, Germany	Closing remarks

